Clonazepam Alternatives Compared
| Clonazepam | Abilify Maintena | Lamictal |
|
|---|
| Clonazepam | Abilify Maintena (aripiprazole) | Lamictal (lamotrigine) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Clonazepam may reduce seizure frequency in specific seizure disorders and can be used short-term for panic disorder, to relieve anxiety, or to sedate. When used long-term it can cause dependence and... View more |
Prescription only
Prescribed for Bipolar Disorder, Schizophrenia. Abilify Maintena may also be used for purposes not listed in this medication guide. |
Prescription only
Lamictal is used to decrease the frequency and severity of seizures in some types of epilepsy and also to stabilize mood in bipolar disorder. Rarely, Lamictal may cause a potentially fatal rash... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Clonazepam | More about Abilify Maintena (aripiprazole) | More about Lamictal (lamotrigine) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Clonazepam has an average rating of 8.1 out of 10 from a total of 2026 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 12% reported a negative effect. |
Abilify Maintena has an average rating of 6.1 out of 10 from a total of 56 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 31% reported a negative effect. |
Lamictal has an average rating of 7.9 out of 10 from a total of 737 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Commonly reported side effects include:
See also: clonazepam side effects in more detail. |
See also: Abilify Maintena side effects in more detail. |
Common side effects include:
See also: Lamictal side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all clonazepam prices |
View all Abilify Maintena prices and generic prices |
View all Lamictal prices and generic prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Klonopin | Other aripiprazole brands include: Abilify, Abilify Asimtufii, Abilify MyCite, Aristada, Aristada Initio | Other lamotrigine brands include: Lamictal CD, Lamictal ODT, Lamictal XR, Subvenite | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
40 hours |
146 hours |
25.7 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 510 drugs are known to interact with clonazepam:
|
A total of 701 drugs are known to interact with Abilify Maintena:
|
A total of 282 drugs are known to interact with Lamictal:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
June 04, 1975 |
N/A |
December 27, 1994 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.